Digital Look

Welcome to Digital Look++,
you are not logged in

Advanced Search | Company A-Z | Feedback

AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

11,042.00p

Change Today:

-164.00p
52 Week High: 13,276.00
52 Week Low: 9,501.00

Currency: UK Pounds
Shares Issued: 1,550.29m
Volume: 2,329,887

Market Cap: £171,184m
RiskGrade: 123

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart (31-10-2024)

6 Month Chart

More AstraZeneca charts

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

	Latest	F'cast
Div Yield	2.0%	0.0%
Div Cover	1.3	2.6
Op Mrgn	17.9%	28.9%
ROCE	62.6%

	Latest	F'cast
P/E	37.0	18.7
PEG	0.5	0.2
Pr/Revenue	4.8	3.4
Pr/Book	5.6

	Latest	F'cast
Revenue	3.3%	-11.4%
PBT	175.8%	70.1%
EPS	81.1%	110.5%
DPS	n/a	-35.7%

AstraZeneca Fundamentals

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-19	24,384.00	1,548.00	103.00¢	95.3	n/a	-39%	280.00¢	2.9%
31-Dec-20	26,617.00	3,916.00	244.00¢	38.7	0.3	+137%	280.00¢	3.0%
31-Dec-21	37,417.00	(265.00)	8.00¢	1,399.2	n/a	-97%	287.00¢	2.6%
31-Dec-22	44,351.00	2,501.00	212.00¢	68.3	0.0	+2,550%	290.00¢	2.0%
31-Dec-23	45,811.00	6,899.00	384.00¢	35.6	0.4	+81%	290.00¢	2.1%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-24	52,352.71	15,139.28	623.97p	17.7	0.2	+110%	240.64p	0.0%
31-Dec-25	56,374.48	17,637.45	719.67p	15.3	1.0	+15%	252.40p	0.0%
31-Dec-26	59,895.77	19,969.19	797.70p	13.8	1.3	+11%	264.65p	0.0%

AstraZeneca forecasts

AstraZeneca Company Announcements

AZN China President under investigation	30-Oct-2024	13:00	RNS
Wainzua recommended for approval in the EU	21-Oct-2024	07:00	RNS
AstraZeneca licenses lipid lowering Lp(a) asset	07-Oct-2024	09:30	RNS

More astrazeneca company announcements

AstraZeneca ShareCast News

AstraZeneca China president under investigation	30-Oct-2024	ShareCast
AstraZeneca's nerve damage treatment recommended...	21-Oct-2024	ShareCast
Hutchmed reports positive results from AstraZene...	16-Oct-2024	ShareCast

More AstraZeneca ShareCast news

AstraZeneca Top Newspaper Links

Fighting Frenchman shows us how as he ensures As...	30-Dec-2014	Daily Mail
Exclusive: UK firms vie for share of £170bn in A...	08-Dec-2014	The Independent
MARKET REPORT: Ariad on the up amid growing spec...	04-Dec-2014	Daily Mail

Latest AstraZeneca Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

AstraZeneca Market Data

Currency	UK Pounds
Share Price	11,042.00p
Change Today	-164.00p
% Change	-1.46 %
52 Week High	13,276.00
52 Week Low	9,501.00
Volume	2,329,887
Shares Issued	1,550.29m
Market Cap	£171,184m
RiskGrade	123